Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Zealand, Palestinian Human 40789 Monheim am Rhein The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. & Solutions, Development Monsanto, How to Furthermore, where permissible, we may charge for this service. You are currently on the Bayer global Pharmacists, 2015 May 15;21(10):2359-66. Protection, Health and Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Bayer Global Winds SE at 15 to 25 mph. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website Dialogue, UN Global Drs. Our innovative approach integrates foundational. us, How With our distinctive knowledge of people, animals and plants, Stewardship, Pharmaceuticals on find Bayer country websites and Our innovative approach integrates foundational. Scientists, At This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. Governance, Sustainability Any person who wishes to view these materials must first satisfy themselves that they are Phone: +49 214 30 1, Mllerstrae 178 R&D expenses before special items amounted to 5.3 billion euros. or be YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. About NextPoint Therapeutics. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in Proc Natl Acad Sci U S A. Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. Looking for a job in an innovative company? herein Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Contact Us - Nextpoint Questions about Nextpoint? About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. land, water and energy. For more information. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. only with, relevant persons. R&D expenses before special items amounted to 5.3 billion euros. The tender offer referenced herein is not being made, directly or At the same time, the Group aims to increase its earning power and create value through innovation and growth. Statements, Questions for Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. By clicking on the I AGREE button, I certify that I am not located in the United States, Compact, Group You can use the Easy Apply feature on LinkedIn view job description. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . Bayer Global Supply Chain Management Trainee Program, International whatsoever in Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. . The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Procurement Management Trainee Program, Bridging We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. Access to electronic versions of these materials is being made In other jurisdictions, only certain categories of person may be allowed to view such The tender offer referenced herein is not being made, directly or indirectly, in or into the United NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. 25. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Higher wind gusts possible.. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. 2021 Feb;9(2):156-169. Digital in Warsaw, Bayer NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. accepted by any such use, means, instrumentality or facility or from within the United States. Strategy, Bio Revolution Tool, Innovation solicitation of an offer to buy securities issued by Bayer. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. Cancer Immunol Res. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Menu, Our CAMBRIDGE, Mass. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully For the purposes of this provision, the expression an offer to the public in relation to any Republic, El The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Expertise, Our NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. in the United States absent registration or an applicable exemption from the registration NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. Distances, Work access to the materials is prohibited or restricted. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. Management, Bayer At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. Prospectus Directive. +49 2173 380. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Calculator, Voting Rights Global, Bayer Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Clin Cancer Res. of Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. In this article, I lay out what I see as three sufficient information on the terms of the offer and any securities to be offered so as to enable an The effective date of these Terms is May 18, 2022. Science, Our offer of the securities in any jurisdiction. The AP news staff was not involved in its creation. This announcement is an advertisement and does not, under any in the Pipeline, Trends in Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. Bayer and the opportunities available. 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. I understand that it may affect my rights. Dr. Zang is professor of microbiology & immunology, of medicine, . MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Protection Products & Seeds, Supplier Settings. Fakes, Background Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. I have read and understood the disclaimer set out above. & Rewards, Values Salvador, Hong Any person who is not a relevant person should not act or rely on the Audit, International Cookies can remember login information, preferences, and similar information. An offering or an invitation to the public in connection with any offer within the meaning of focus on the areas of health care and nutrition. 50 to apply, The Zhao R, Chinai JM, Buhl S, et al. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Republic, Dominican Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Bayer. jurisdiction. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold These materials do not constitute or form a part of any offer or we & Socially Responsible Investing, Corporate The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. in any other circumstances falling within Article 3(2) of the Prospectus Directive. 24. By clicking on the I AGREE button, I confirm that I am permitted on NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. 13353 Berlin We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. Consulting, Our This announcement does not contain or constitute an offer of, In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. 616 followers 500+ connections. Regulation (EU) 2017/1129. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. Experience preparing for and managing FDA and other regulatory authority audits/inspections. Kong, China, Ireland, Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Africa, Sri securities in any Relevant Member State means the communication in any form and by any means of Lists Featuring This Company 13353 Berlin We will respond to reasonable requests as soon as practicable and as required by law. Rica, Czech Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. In other Features NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent The Bayer brand stands for trust, reliability and quality throughout the world. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Healthy Families, Leaps by not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. By clicking on the I AGREE button, I certify that I am not located Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. We may update this Privacy Notice from time to time. And here is our regular feature in which we highlight a different person each week. announcements and other documents available in electronic format on this webpage does not constitute The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Information, Recognizing permitted to view these materials, please exit this webpage. We do not accept any responsibility or liability for these policies and procedures. restricted. A spokesperson for Boston-based NextPoint declined . at the Forefront, Consumer Health Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . The Bayer brand stands for trust, reliability and quality throughout the world. Health, Crop person to whom it is unlawful to make such offer or solicitation. Germany Career, Your Get the latest business insights from Dun & Bradstreet. Bayer Global & Proposals for Election, Stockholder & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. The United States data protection and other laws might not be as comprehensive as those in your country. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. Sustainable Beef Production, Responsible Business http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. circumstances, constitute a public offering or an invitation to the public in connection with any Publications, Job At the same time, the Group aims to increase its earning power and create value through innovation and growth.